Kin‐hang Kok - Infectious Diseases

Author Information

Kin-hang Kok is a distinguished researcher affiliated with the State Key Laboratory of Emerging Infectious Diseases at The University of Hong Kong, located in Pokfulam, Hong Kong Special Administrative Region, China. His work primarily focuses on infectious diseases, with a particular emphasis on understanding and combating viral infections such as SARS-CoV-2, the virus responsible for COVID-19.

Research Contributions

Kin-hang Kok has made significant contributions to the field of infectious diseases, particularly in understanding the mechanisms of coronavirus infections and developing strategies to mitigate their impact. His recent research includes the development of a nasal Omicron vaccine booster to elicit potent neutralizing antibody responses against emerging SARS-CoV-2 variants, and the investigation of viral and host determinants that influence the efficiency of SARS-CoV-2 infection in the human lung. Additionally, his work has explored the effects of environmental factors on viral infections and the potential therapeutic avenues to reduce viral pathogenesis and severity.

Aliases

Kin-hang Kok has published under several aliases, including Kin‑hang Kok, Kin-hang. Kok, K Kok, and Kin Hang Kok. These variations reflect different formatting and stylizations of his name across various publications and databases.

Publication and Citation Metrics

Metric	Value
Total Citation Count	18,045
H-Index	40
Paper Count	117

Publications:

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants

DOI: 10.1080/22221751.2022.2053365

Year: 2022

Co-circulation of two SARS-CoV-2 variant strains within imported pet hamsters in Hong Kong

DOI: 10.1080/22221751.2022.2040922

Year: 2022

Low Environmental Temperature Exacerbates Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Golden Syrian Hamsters.

DOI: 10.1093/cid/ciab817

Year: 2021

Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis in mouse model

DOI: 10.1093/cid/ciab707

Year: 2021

Host-derived lipids orchestrate pulmonary γδ T cell response to provide early protection against influenza virus infection

DOI: 10.1038/s41467-021-22242-9

Year: 2021

Mining of linear B cell epitopes of SARS-CoV-2 ORF8 protein from COVID-19 patients

DOI: 10.1080/22221751.2021.1931465

Year: 2021

Emergence of a Severe Acute Respiratory Syndrome Coronavirus 2 virus variant with novel genomic architecture in Hong Kong

DOI: 10.1093/cid/ciab198

Year: 2021

Host and viral determinants for efficient SARS-CoV-2 infection of the human lung

DOI: 10.1038/s41467-020-20457-w

Year: 2021

Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity

DOI: 10.1126/sciadv.abf8577

Year: 2021

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2.

DOI: 10.1038/s41586-021-03431-4

Year: 2021

How is Quarantine Different From Isolation?

What are the Treatments for HSV?

What Are the Symptoms of Diseases Transmitted by Culex?

What are the Challenges in Controlling Dengue Hemorrhagic Fever?

What are the Symptoms of Chlamydia?

What Are Functional Assays?

What are the Strategies to Overcome These Challenges?

What are condoms?

How Can Hepatitis B be Prevented?

What Are the General Principles of Treatment?

Partnered Content Networks

Relevant Topics